CYP2D6 polymorphism is not crucial for the disposition of selegiline* (Q60682679)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

CYP2D6 polymorphism is not crucial for the disposition of selegiline (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

Anttila M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Dahl ML

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Karnani H

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Nyman L

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Taavitsainen P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Pelkonen O

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Bertilsson L

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

language of work or name

English

0 references

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

402-411

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Effect of deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Polymorphic hydroxylation of Debrisoquine in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Urinary excretion of amphetamine and 4'-hydroxyamphetamine by Sprague Dawley and dark Agouti rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Lack of adverse interactions between concomitantly administered selegiline and citalopram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Fluoxetine impairs clearance of alprazolam but not of clonazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Relevance of genetic polymorphism in drug metabolism in the development of new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Portable device for quantifying parkinsonian wrist rigidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Association between the oxidative polymorphism and early onset of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990071-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(98)90071-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797797%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference